Dr. med. Anja Hagen, MPH, Medical Quality Manager

Head of Research Focus Evidence Based Medicine & Health Technology Assessment

Phone: +49 (0)511-532-9344

Fax: +49 (0)511-532-5376

E-mail: Hagen.Anja@mh-hannover.de

Fields of activity

Technology assessment and innovation management

Career

Since 2012 Head of the research focus Evidence Based Medicine & Health Technology Assessment

2012 Dissertation for Dr. med. at the Hannover Medical School

2010 Completed further training as an investigator for clinical trials

2004 Completed curriculum "Medical Quality Management" according to ÄZQ

Since 2002 Research assistant at the Institute of Epidemiology, Social Medicine and Public Health Research, Hannover Medical School

2001-2002 AIP activity (6 months, social medicine)

2000-2002 Part-time supplementary study program in Population Medicine and Public Health, Hannover Medical School

2000 AIP activity (6 months, general medicine)

1998 Member of the supervisory board of Quick-Tools AG Medizingeräte u. -systeme, AIP activity (6 months, surgery)

1997 Graduated in medicine (3rd state examination)

Since 1994 Management and consulting in medical technology companies and in the outpatient sector

1992 Additional studies in dentistry

1987 Commencement of medical studies, J.W. Goethe University, Frankfurt

Projects in the research area "Evidence Based Medicine & Health Technology Assessment"

Cochrane review: Growth factors for angiogenesis in peripheral arterial disease.

Abstract

BACKGROUND: Peripheral artery disease (PAD) is associated with a high clinical and socioeconomic burden. Treatments to alleviate the symptoms of PAD and decrease the risks of amputation and death are a high societal priority. A number of growth factors have shown a potential to stimulate angiogenesis. Growth factors delivered directly (as recombinant proteins), or indirectly (e.g. by viral vectors or DNA plasmids encoding these factors), have emerged as a promising strategy to treat patients with PAD.

OBJECTIVES: To assess the effects of growth factors that promote angiogenesis for treating people with PAD of the lower extremities.

SEARCH METHODS: The Cochrane Vascular Information Specialist searched the Specialized Register (June 2016) and CENTRAL (2016, Issue 5). We searched trial registries for details of ongoing or unpublished studies. We also checked the reference lists of relevant publications and, if necessary, tried to contact the trialists for details of the studies.

SELECTION CRITERIA: We included randomized controlled trials comparing growth factors (delivered directly or indirectly) with no intervention, placebo or any other intervention not based on the growth factor's action in patients with PAD of the lower extremities. The primary outcomes were limb amputation, death and adverse events. The secondary outcomes comprised walking ability, haemodynamic measures, ulceration and rest pain.

DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials and assessed the risk of bias. We used outcomes of the studies at low risk of bias for the main analysis and of all studies in the sensitivity analyses. We calculated odds ratios (OR) for dichotomous outcomes and mean differences for continuous outcomes with 95% confidence intervals (CI). We evaluated statistical heterogeneity using the I2 statistic and Cochrane's Q test. We conducted meta-analysis for the overall effect and for each growth factor as a subgroup analysis using OR in a fixed-effect model. We evaluated the robustness of the results in a sensitivity analysis using risk ratio (RR) and/or a random-effects model. We also assessed the quality of the evidence for each outcome.

MAIN RESULTS: We included 20 trials in the review and used 14 studies (on approximately 1400 participants) with published results in the analyses. Six published studies compared fibroblast growth factors (FGF), four studies hepatocyte growth factors (HGF) and another four studies vascular endothelial growth factors (VEGF), versus placebo or no therapy. Six of these studies exclusively or mainly investigated participants with intermittent claudication and eight studies exclusively participants with critical limb ischaemia. Follow-up generally ranged from three months to one year. Two small studies provided some data at 2 years and one of them also at 10 years.The direction and size of effects for growth factors on major limb amputations (OR 0.99, 95% CI 0.71 to 1.38; 10 studies, N = 1075) and death (OR 0.99, 95% CI 0.69 to 1.41; 12 studies, N = 1371) at up to two years are uncertain. The quality of the evidence is low due to risk of bias and imprecision (at one year, moderate-quality evidence due to imprecision). However, growth factors may decrease the rate of any limb amputations (OR 0.56, 95% CI 0.31 to 0.99; 6 studies, N = 415). The quality of the evidence is low due to risk of bias and selective reporting.The direction and size of effects for growth factors on serious adverse events (OR 1.09, 95% CI 0.79 to 1.50; 13 studies, N = 1411) and on any adverse events (OR 1.10, 95% CI 0.73 to 1.64; 4 studies, N = 709) at up to two years are also uncertain. The quality of the evidence is low due to risk of bias and imprecision (for serious adverse events at one year, moderate-quality evidence due to imprecision).Growth factors may improve haemodynamic measures (low-quality evidence), ulceration (very low-quality evidence) and rest pain (very low-quality evidence) up to one year, but they have little or no effect on walking ability (low-quality evidence). We did not identify any relevant differences in effects between growth factors (FGF, HGF and VEGF).
AUTHORS' CONCLUSIONS:
The results of this review do not support the use of therapy with the growth factors FGF, HGF or VEGF in people with PAD of the lower extremities to prevent death or major limb amputation or to improve walking ability. However, the use of these growth factors may improve haemodynamic measures and decrease the rate of any limb amputations (probably due to preventing minor amputations) with an uncertain effect on adverse events; an improvement of ulceration and rest pain is very uncertain. New trials at low risk of bias are needed to generate evidence with more certainty.

Ultrasound screening for abdominal aortic aneurysms
Measures to promote health behavior in men
Bone substitutes for the treatment of traumatic fractures of the extremities
CT coronary angiography versus conventional invasive coronary angiography in CHD-diagnosis
Percutaneous coronary interventions in addition to optimal drug therapy for stable angina pectoris
Infection protection in knee arthroplasty
Specific immunotherapy (SIT) for the treatment of allergic rhinitis
Methods for the early evaluation of innovative medical technologies during development
Joint endoprosthesis register for Germany
Instruments for risk prediction for cardiovascular diseases
Drug-eluting stents compared to bypasssurgery for coronary heart disease
Intravascular brachytherapy for peripheral arterial occlusive disease (PAD)
Regulation of the inclusion of innovative non-drug technologies in the benefits catalog of payers financed on a solidarity basis
Measures to improve compliance and adherence in drug therapy with patients with PAD. Adherence in drug therapy with regard to therapeutic success
Benefits and risks of hormonal contraceptives in women
Laparoscopic vs. open appendectomy. Systematic review of medical efficacy and health economic analysis
Reduction of the restenosis rate through the use of coated stents in coronary heart disease
Innovation-related technology assessment of cardiovascular implants

Teaching

Human medicine study programmes at MHH Cross-sectional subject epidemiology (systematic reviews and meta-analyses)

Human medicine study programmes at the MHH Cross-sectional subject social medicine (evidence-based medicine)

Cross-sectional subject Health Economics (Seminar Management in Healthcare) on the MHH Human Medicine degree program

Human medicine course at the MHH Compulsory elective course (systematic literature research and study selection)

Master's program in Public Health, basic course in epidemiology (systematic reviews and meta-analyses)

Master's degree program in Public Health Compulsory elective course (HTA & EBM)

HTA reports

Gorenoi V, Bruns F, Mertz M, Kahrass H, Krauth C, Kula A, Beck S, Hagen A (2023). "Fibromatoses of the hand (Dupuytren's disease) and/or foot (Ledderhose disease). Do patients benefit from radiotherapy?". IQWiG Health Technology Assessment publication series, 2023, vol. no. 1374, 135 pages, ISSN: 1864-2500 (HT21-01).

Gorenoi V, Sturm C, Bonetti F, Mertz M, Kahrass H, Schnarr A, Krauth C, Beck S, Hagen A (2022). Mobility disorders: Does the Feldenkrais Method help? IQWiG publication series Health Technology Assessment, vol. 1374, 2022, ISSN: 1864-2500 (139 pages)

Brender R, Gorenoi V, Hagen A (2021). Identification of obsolete technologies to avoid ineffective treatments and bad investments in the German healthcare system. Publication series Health Technology Assessment, VOL: 151, 1st edition 2021. ISSN: 1864-9645, DOI 10.3205/hta000151L

Dreier M, Krüger K, Walter U, Hagen A (2021). Smoking ban in publicly accessible areas. Publication series Health Technology Assessment, VOL: 138, 1st edition 2021. ISSN: 1864-9645, 10.3205/hta000138L

Gorenoi V, Schippert C, Mertz M, Kahrass H, Krauth C, Beck S, Hagen A (2021). Pain in endometriosis. Do other procedures help instead of pain medication? Cologne: IQWiG, 2021, 200 pages (IQWiG Health Technology Assessment publication series, vol. no. 1233)

Kula A, Strech D, Mertz M, Krüger K, Liersch S, Walter U, Hagen A (2021). Obesity prevention programs in schools. Publication series Health Technology Assessment, VOL: 140, 1st edition 2021. ISSN: 1864-9645, DOI 10.3205/hta000140L

Gorenoi V, Tavassol F, Krauth C, Mertz M, Kahrass H, Strech D, Beck S, Seidel G, Hagen A (2019). Cleft lip and palate: Does the use of nasoalveolar molding prior to surgery lead to better outcomes? IQWiG HTA topic review series, Cologne, ISSN: 1864-2500

Gorenoi V, Brehm MU, Koch A, Hagen A. Growth factors for angiogenesis in peripheral arterial disease. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD011741. DOI: 10.1002/14651858.CD011741.pub2

Gorenoi V, Brehm MU, Koch A, Hagen A. Growth factors for angiogenesis in peripheral arterial disease. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD011741. DOI: 10.1002/14651858.CD011741 .

Hagen A, Gorenoi V, Walter U. Measures to promote men's health behavior. DIMDI HTA series, Volume 133; 1st edition, Cologne 2015.

Hagen A, Gorenoi V, Schönermark MP. Bone substitutes for the treatment of traumatic fractures of the extremities. Publication series HTA of the DIMDI, Volume 119; 1st ed., Cologne 2012.

Gorenoi V, Schönemark MP, Hagen A. CT coronary angiography versus conventional invasive coronary angiography in CHD diagnostics. DIMDI HTA publication series, Volume 117; 1st ed., Cologne 2012.

Gorenoi V, Schönermark MP, Hagen A. "Percutaneous coronary interventions in addition to optimal drug therapy for stable angina pectoris". DIMDI HTA series, Volume 115; 1st edition, Cologne 2011 (109 pages). ISSN: 1864-9645.

Gorenoi V, Schönermark MP, Hagen A. "Infection protection in knee arthroplasty". DIMDI HTA series, Volume 104; 1st edition, Cologne 2010 (74 pages). ISSN: 1864-9645.

Hagen A, Gorenoi V, Schönermark MP. "Specific immunotherapy (SIT) for the treatment of allergic rhinitis" DIMDI HTA series, Volume 96; 1st edition, Cologne 2010 (86 pages). ISSN: 1864-9645.

Gorenoi V, Schönermark MP, Hagen A. "Instruments for risk prediction for cardiovascular diseases". DIMDI HTA series, Volume 90; 1st Ed. 2009, 84 pp. Cologne, ISSN: 1864-9645.

Gorenoi V, Schönermark MP, Hagen A. "Joint arthroplasty register for Germany". DIMDI HTA series, Volume 92; 1st edition, Cologne 2009 (100 pages). ISSN: 1864-9645.

Bartelmes M, Neumann U, Lühmann D, Schönermark MP, Hagen A. "Methoden zur frühen entwicklungsbegleitenden Bewertung innovativer medizinischer Technologien". Publication series HTA of the DIMDI, Volume 94; 1st edition, Cologne 2009 (120 pages). ISSN: 1864-9645.

Gorenoi V, Dintsios ChM, Schönermark MP, Hagen A. Drug-eluting stents compared with bypass surgery for coronary artery disease. DIMDI HTA series, Volume 72; 1st edition, Cologne 2008 (88 pages). ISSN: 1864-9645.

Gorenoi V, Dintsios ChM, Schönermark MP, Hagen A. Intravascular brachytherapy for peripheral arterial occlusive disease (PAD). DIMDI HTA series, Volume 75; 1st edition, Cologne 2008 (84 pages). ISSN: 1864-9645.

Neumann U, Hagen A, Schönermark M. Regulation of the inclusion of innovative non-drug technologies in the benefit catalog of solidary financed payers. DIMDI publication series, vol. 64 (155 pages), 1st edition, Cologne 2007. ISSN: 1864-9645.

Gorenoi V, Schönermark MP, Hagen A. Measures to improve compliance and adherence in drug therapy with regard to therapeutic success. DIMDI HTA series, Volume 65; 1st edition, Cologne 2007 (75 pages). ISSN: 1864-9645.

Gorenoi V, Schönermark MP, Hagen A. Benefits and risks of hormonal contraceptives in women. DIMDI HTA series, Volume 56; 1st edition, Cologne 2007 (114 pages). ISSN: 1864-9645.

Gorenoi V, Dintsios ChM, Schönermark MP, Hagen A. Laparoscopic vs. open appendectomy. Systematic review of medical effectiveness and health economic analysis. DIMDI HTA series, Volume 49; 1st edition, Cologne 2006 (100 pages). ISSN: 1864-9645.

Gorenoi V, Dintsios ChM, Hagen A. Reduction of the restenosis rate by using coated stents in coronary artery disease. DIMDI HTA series, Volume 27; 1st edition, Cologne 2005 (241 pages). ISSN: 1864-9645.

Other publications

Gorenoi V, Brehm MU, Koch A, Hagen A. Growth factors for angiogenesis in peripheral arterial disease. Cochrane Database of Systematic Reviews 2015; 6: CD011741.

Gorenoi V, Hagen A. Overview of Risk-Estimation Tools for Primary Prevention of Cardiovascular Diseases in European Populations. Cent Eur J Public Health 2015; Vol.23 (2): 91-99.

Gorenoi V, Hagen A. SR/PS method for the inclusion of primary study data from systematic reviews in the assessment of medical technologies. Z. Evid. Fortbild. Qual. Health Care 2014; Vol.108(5-6): 325-332.

Gorenoi V, Hagen A. Percutaneous coronary intervention in addition to optimal drug therapy for stable coronary artery disease. A systematic review and meta-analysis. Dtsch Med Wochenschr 2014; 139: 1039-1045.

Hagen A, Gorenoi V, Schönermark MP. Bone graft substitutes for the treatment of traumatic fractures of the extremities. GMS Health Technol Assess 2012; Vol. 8; Doc04. ISSN: 1861-8863.

Gorenoi V, Schönemark MP, Hagen A. CT coronary angiography vs. invasive coronary angiography in CHD. GMS Health Technol Assess 2012; Vol. 8; Doc 2. ISSN: 1861-8863.

Gorenoi V, Schönermark MP, Hagen A. "Percutaneous coronary intervention with optimal medical therapy vs. optimal medical therapy alone for patients with stable angina pectoris". GMS Health Technol Assess 2011; Vol. 7; Doc7. ISSN: 1861-8863.

Gorenoi V, Schönermark MP, Hagen A. Evidence on infection control measures in knee arthroplasty. Management & Hospital 2011; Vol 30 (4):24

Gorenoi V, Schönermark MP, Hagen A. "Prevention of infection after knee arthroplasty". GMS Health Technol Assess 2010; Vol 6; Doc. 10. ISSN: 1861-8863

Hagen A, Gorenoi V, Schönermark MP. "Specific immunotherapy (SIT) in the treatment of allergic rhinitis". GMS Health Technol Assess 2010; Vol 6; Doc. 01. ISSN: 1861-8863

Gorenoi V, Schönermark MP, Hagen A. Assessments tools for risk prediction of cardiovascular diseases. GMS Health Technol Assess 2009, Vol. 5; Doc.11. ISSN: 1861-8863.

Bartelmes M, Neumann U, Lühmann D, Schönermark MP, Hagen A. "Methods for assessment of innovative medical technologies during early stages of development" GMS Health Technol Assess 2009; Vol. 5; Doc.15. ISSN: 1861-8863

Gorenoi V, Schönermark MP, Hagen A. "Arthroplasty register for Germany" [Joint endoprosthesis register for Germany]. GMS Health Technol Assess 2009; Vol. 5; Doc.13. ISSN: 1861-8863

Gorenoi V, Dintsios ChM, Schönermark MP, Hagen A. Health-Economic Modeling on the Use of Drug-Eluting Stents versus Coronary Artery Bypass Graft Surgery in Coronary Heart Disease [Health-Economic Modeling on the Use of Drug-Eluting Stents versus Coronary Artery Bypass Graft Surgery in Coronary Heart Disease]. Heart 2009, 34:231-239.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Intravascular brachytherapy for peripheral arterial occlusive disease: systematic review of medical efficacy and health economic modeling]. Z. Evid. Fortbild. Qual. Gesundh. wesen (ZEFQ) 2009, 103: 331-340.

Gorenoi V, Dintsios ChM, Schönermark MP, Hagen A. Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease [Drug-eluting stents compared to bypass surgery in coronary artery disease]. GMS Health Technol Assess 2008, Vol. 4; Doc.13. ISSN: 1861-8863.

Gorenoi V, Hagen A, Schönermark MP. Randomized trials: an important methodological aspect. Dtsch Arztebl 2008, 105(20): A-1071.

Gorenoi V, Dintsios ChM, Schönermark MP, Hagen A. Intravascular brachytherapy for peripheral vascular disease [Intravascular brachytherapy for peripheral arterial occlusive disease (PAD)]. GMS Health Technol Assess 2008, Vol. 4; Doc.08. ISSN: 1861-8863.

Hagen A, Hessabi HK, Gorenoi V, Schönermark MP. Kosteneffectiveness Bewertung Prediktiver Molekulardiagnostik am Beispiel des Hereditären Nichtpolypösen Kolorektalkarzinoms (HNPCC) [Cost-Effectiveness Evaluation of Predictive Molecular Diagnostics using the Example of Hereditary Non-Polyposis Colorectal Cancer (HNPCC)]. Public Health 2008, 70: 18-27, ISSN 0941-3790.

Gorenoi V, Schönermark MP, Hagen A. Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes]. GMS Health Technol Assess 2007, Vol. 3; Doc.14. ISSN: 1861-8863.

Neumann U, Hagen A, Schönermark M. Procedures and Criteria for the regulation of innovative non-medicinal technologies into the benefit catalogue of solidly financed health care insurances. [Regulation of the inclusion of innovative non-medicinal technologies into the benefit catalogue of solidly financed health care insurances]. GMS Health Technol Assess 2007, 3:Doc13:1-12. ISSN: 1861-8863.

Gorenoi V, Schönermark MP, Hagen A. Benefits and risks of hormonal contraception for women. GMS Health Technol Assess 2007, Vol. 3; Doc.06. ISSN: 1861-8863.

Gorenoi V, Dintsios ChM, Schönermark MP, Hagen A. Laparoscopic versus open appendectomy, a systematic review and health economic analysis [Laparoscopic versus open appendectomy, systematic review of medical effectiveness and health economic analysis]. GMS Health Technol Assess 2006, Vol. 2; Doc.22. ISSN: 1861-8863.

Gorenoi V, Dintsios ChM, Hagen A. Coated stents to prevent restenosis in coronary heart disease [Reducing the rate of restenosis by using coated stents in coronary heart disease]. GMS Health Technol Assess 2005, Vol. 1; Doc.06. ISSN: 1861-8863.

Hagen A, Krauth C, Gerhardus A, Dintsios CM. Competence Centre for Cardiovascular Implants. Final report 1st funding period (4/2001-3/2004). Funding recipient: Hannover Medical School (MHH). Axel Haverich; Sabine Barlach, funding code BMBF 03N4023.

Abstracts

Kula A, Liersch S, Krüger K, Walter U, Hagen A (2019). Obesity prevention - is school an effective place? A systematic review, European Journal of Public Health, Volume 29, Issue Supplement_4, November 2019, ckz187 .049 , doi.org/10.1093/eurpub/ckz187.049

Kula A, Wiedel C, Borutta B, Kaeding T, Vehling M, Hagen A, Goldapp C, Ommen O, Walter U. Integrated Interventions in Diet, Physical Activity and Life Skills for children and teens - Review. European Journal of Public Health 2015; 25(3): 165.

Gorenoi V, Hagen A. "Presentation of a new method for the evaluation of medical technologies with inclusion of study data from systematic reviews" Poster presentation at the 15th Annual Conference of the German Network for Evidence-based Medicine e.V. March 13-15, 2014, Halle, Germany. Abstract P14e.

Gorenoi V, Schönermark MP, Hagen A. The cost-effectiveness of CT coronary angiography versus invasive coronary angiography in CHD diagnostics. Short presentation at the 12th German Congress for Health Services Research October 23-25, 2013, Berlin, Germany. Abstract volume DKVF 2013, Abstract 176.

Gorenoi V, Schönermark MP, Hagen A. Evidence on the diagnostic accuracy of CT coronary angiography versus invasive coronary angiography in CHD diagnosis. Poster presentation at the 14th Annual Meeting of the German Network for Evidence-based Medicine, March 15-16, 2013, Berlin, Germany. Abstract P92.

Gorenoi V, Schönermark MP, Hagen A. "Cost-effectiveness of percutaneous coronary interventions in addition to optimal drug therapy in stable angina pectoris". Poster presentation at the 11th German Congress for Health Services Research. September 27-29, 2012, Dresden, Germany. Deutsche Medizinische Wochenschrift, Vol. 137, Suppl. 3. abstract 91.

Hagen A, Gorenoi V, Schönermark MP. "Bone graft substitutes for the treatment of traumatic fractures of the extremities" Poster presentation, 9th HTAi Annual Meeting, June 23-27, 2012 Bilbao, Gac Sanit. 2012; 26(espec Congr 2): abstract 479, p167.

Gorenoi V, Schönermark MP, Hagen A. "Percutaneous coronary intervention with optimal medical therapy vs. optimal medical therapy alone for patients with stable angina pectoris. Medical evaluation." Poster presentation, 9th HTAi Annual Meeting, June 23-27, 2012 Bilbao, Gac Sanit. 2012; 26(espec Congr 2): abstract 203, p158.

Gorenoi V, Schönermark MP, Hagen A. "Percutaneous coronary intervention with optimal medical therapy vs. optimal medical therapy alone for patients with stable angina pectoris. Health-economic evaluation." Poster presentation, 9th HTAi Annual Meeting, June 23-27, 2012 Bilbao, Gac Sanit. 2012; 26 (espec Congr 2): abstract 204, p187.

Gorenoi V, Schönermark MP, Hagen A. "Percutaneous coronary interventions in addition to optimal drug therapy for stable angina pectoris. Medical efficacy". Poster presentation at the 13th Annual Meeting of the German Network for Evidence-based Medicine e.V. March 15-17, 2012, Hamburg, Germany. Abstract P 7g.

Gorenoi V, Schönermark MP, Hagen A. "Instruments for individualized risk prediction of cardiovascular diseases in Germany". Poster presentation at the 12th Annual Conference of the German Network for Evidence-based Medicine e.V. March 24-26, 2011, Berlin, Germany. Abstract P 6d.

Gorenoi V, Schönermark MP, Hagen A. "Potential benefits and difficulties of introducing a joint arthroplasty registry in Germany". Poster at the 9th German Congress for Health Services Research, September 30 to October 02, 2010, Bonn, Germany. Abstract volume DKVF/APS 2010, Abstract PS30.

Gorenoi V, Schönermark MP, Hagen A. "Risk prediction tools for the individualized prevention of cardiovascular diseases in Germany". Presentation at joint congress of DGSMP, DGEpi and EUMASS, September 21-25, 2010, Berlin, Germany. Das Gesundheitswesen 2010, Vol. 72 Congress proceedings; Abstract V189.

Gorenoi V, Schönermark MP, Hagen A. "Assessment tools for risk prediction of cardiovascular diseases". Poster presentation at the VII HTAi Annual Meeting, June 6-9, 2010 Dublin, Book of Abstracts, Abstract M1-12.

Hagen A. Meeting abstract "Internationally existing joint arthroplasty registers and conclusions for Germany", 10th Symposium Health Technology Assessment. Cologne, 18-19.03.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10hta15. DOI: 10.3205/10hta15, URN: urn:nbn:de:0183-10hta154.

Gorenoi V, Schönermark MP, Hagen A. "Instruments for risk prediction for cardiovascular diseases". Presentation at the 8th German Congress for Health Services Research of the DNVF and 43rd Congress of DEAGAM, October 01-03, 2009, Heidelberg, Germany. ZFA Special Issue 2009, Abstract WS272.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Health economic modeling of the use of intravascular brachytherapy for peripheral arterial occlusive disease. Poster presentation at the 10th Annual Meeting of the German Network for Evidence-based Medicine e.V. March 05-07, 2009, Berlin, Germany. Abstract P 6.7.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Intravascular Brachytherapy for Peripheral Vascular Disease. Health Economic Evaluation. Poster presentation at the VI HTAi Annual Meeting, June 22-24, 2009, Singapore, Abstract P22.2.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Intravascular Brachytherapy for Peripheral Vascular Disease. Medical Evaluation. Poster presentation at the VI HTAi Annual Meeting, June 22-24, 2009, Singapore, Abstract P22.1.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Systematic review of the medical effectiveness of intravascular brachytherapy for peripheral arterial disease. Poster presentation at the 10th Annual Meeting of the German Network for Evidence-based Medicine e.V. March 05-07, 2009, Berlin, Germany. Abstract P 4.2.

Hagen A, Neumann U, Schönermark MP. Inclusion of Innovative Non-medicinal Technologies into the Benefit Catalogue of Solidary Health Care Insurances. Poster presentation at the VI HTAi Annual Meeting, June 22 - 24, 2009, Singapore, Abstract P.1.2.

Dintsios CM, Hagen A, Gerhardus A, Krauth C. Tissue Engineering of Valved Venous Cconduits (VVC) versus Conservative Therapy in Patients with Chronic Veous Insufficiency (CVI). A Decision Aanalytic Model using Expert Estimated Utilities based on derived Data from Animal Studies as a Pre-Market Technology Assessment Approach with German Data. Value in Health 2008, 11(6): A406.

Hagen A, Eimer U, Schönermark MP. Regulation of the inclusion of non-drug technologies in the benefit catalog of solidary financed payers in Germany, England, Australia and Switzerland. Poster presentation at the DGSMP conference, September 17-19, 2008, Hanover, Germany Abstract P01-4.

Dintsios CM, Hagen A, Gerhardus A, Krauth C. Tissue engineering of valved venous conduits (VVC) versus conservative therapy in patients with chronic venous insufficiency (CVI). A decision analytic model using expert estimated utilities based on derived data from animal studies as a pre-marketing technology assessment approach with German data. Poster presentation at the ISPOR 11th Annual Congress, 8-11 Nov 2008, Athens, Greece, Abstract PCV80.

Hagen A. Improving compliance and adherence in drug therapy. Meeting abstract 9th Symposium Health Technology Assessment. Cologne, October 17-18, 2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. Doc 08hta05.

Gorenoi V, Schönermark MP, Hagen A. Measures to improve compliance and adherence in drug therapy with regard to therapeutic success. Poster presentation at the 7th German Congress on Health Services Research, 16-18.10. 2008, Cologne, Germany, Abstract P3.9.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Health economic Modeling on the Use of Drug-eluting Stents vs. Coronary Artery Bypass Graft Surgery in Coronary Heart Disease. Poster presentation at the Vth HTAi Annual Meeting, July 6-9, 2008, Montreal, Canada, Abstract T3.14.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Systematic Review on Medical Efficacy of Drug-eluting Stents vs. Coronary Artery Bypass Graft Surgery in Coronary Heart Disease. Poster presentation at the Vth HTAi Annual Meeting, July 6-9, 2008, Montreal, Canada, Abstract M11.1.

Dintsios CM, Gerhardus A, Hagen A, Krauth C. Health economic Modeling on the Use of Drug-eluting Stents vs. Coronary Artery Bypass Graft Surgery in Coronary Heart Disease. Poster presentation at the HTAi 2008 Annual Meeting, July 6-9, 2008, Montreal, Canada, Abstract M3.15.

Dintsios CM, Gerhardus A, Hagen A, Krauth C. Needs assessment (NA) for venous implants in the treatment of chronic venous insufficiency (CVI). In: HTA in context, Poster Presentation at the V Annual Meeting Health Technology Assessment International, 2008, Book of Abstracts: M3.15.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Health economic modeling of the use of drug-eluting stents versus bypass surgery for coronary artery disease. Poster presentation at the 9th Annual Meeting of the German Network for Evidence-based Medicine, February 22-23, 2008, Witten, Germany. Abstract P16. GMS 2008. Doc08 ebmP16. ISBN: 978-3-938975-16-9 .

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Systematic review on the medical efficacy of drug-eluting stents compared to bypass surgery in coronary artery disease. Poster presentation at the 9th Annual Meeting of the German Network for Evidence-Based Medicine, February 22-23, 2008, Witten, Germany. Abstract P15. GMS 2008. Doc08 ebmP15. ISBN: 978-3-938975-16-9 .

Gorenoi V, Schönermark MP, Hagen A. Benefits and risks of hormonal contraceptives in women. Poster presentation at the 2nd National Prevention Congress and 6th German Congress on Health Services Research, October 24-27, 2007, Dresden, Germany. Prevention and Health Promotion 2007, Supplement 1, Volume 2: p.105, Abstract P39.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Laparoscopic vs. open appendectomy. A health economic analysis. Poster presentation at the 2nd National Prevention Congress and 6th German Congress on Health Services Research, October 24-27, 2007, Dresden, Germany. Prevention and Health Promotion 2007, Supplement 1, Volume 2: p.106, Abstract P40.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Laparoscopic vs. open appendectomy, an economical evaluation. Poster presentation at the IV HTAi Annual Meeting, June 17-20, 2007, Barcelona, Spain. Abstract T-096.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Laparoscopic vs. open Appendectomy, a medical evaluation.poster presentation at the IV HTAi Annual Meeting, June 17-20, 2007, Barcelona, Spain. Abstract T-095.
Dintsios Ch.-M., Hagen A., Gerhardus A., Krauth C.. "Needs assessment of cardiovascular implants for the treatment of chronic venous insufficiency (CVI)". in Congress of Medicine and Society, 2007, Vol. 60, http://www.egms.de/en/meetings/gmds2007/07gmds068.shtml.

Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Laparoscopic vs. open appendectomy, systematic review of medical efficacy. Poster presentation at the 8th Annual Meeting of the German Network for Evidence-based Medicine, March 22-24, 2007, Berlin, Germany. Poster P1.1. GMS Conferences (07ebm056).

Hagen A. Methods in the preparation of an HTA report. German Agency for Health Technology Assessment of the German Institute for Medical Documentation and Information. 7th Symposium Health Technology Assessment. Cologne, October 19-20, 2006. Düsseldorf: German Medical Science GMS Publishing House; 2006. Doc 06hta13.

Dintsios CM, Krauth C, Hagen A, Gerhardus A, Schwartz FW. Innovation-related Health Technology Assessment of Cardiovascular Implants. In: Booklet of Abstracts ESF-IfW Conference on The Global Health Economy, New Technology and Medical Decision Making, Normative Models and Empirical Practice, Salzau Castle (Kiel), October, 2006, http://www.uni-kiel.de/ifw/konfer/newtech06/booklet_of_abstracts.pdf.

Gorenoi V, Dintsios CM, Hagen A. Coated vs. uncoated stents in coronary artery disease, systematic review of medical efficacy. Poster presentation at the 42nd Annual Scientific Meeting of the German Society for Social Medicine and Prevention (DGSMP), September 27-29, 2006, Frankfurt am Main / Offenbach. Health Care 2006, Vol. 68, Abstract A47.

Gorenoi V, Hagen A. Drug eluting stents versus coronary artery bypass surgery. Poster presentation at the III. HTAi Annual Meeting, July 2-5, 2006, Adelaide, Australia. Congress supplement, p.88.

Gorenoi V, Dintsios CM, Hagen A. A health economical analysis on the use of coated stents in coronary heart disease. Poster presentation at the III. HTAi Annual Meeting, July 2-5, 2006, Adelaide, Australia. Congress supplement, p.87.

Gorenoi V, Dintsios CM, Hagen A. Evidence on the use of coated coronary stents. Poster presentation at the III. HTAi Annual Meeting, July 2-5, 2006, Adelaide, Australia. Congress supplement, p.118.

Gorenoi V, Dintsios CM, Hagen A. Coated stents for the prevention of restenosis in CHD - a health economic analysis. Poster presentation at the 5th German Congress on Health Services Research, May 12, 2006, Ludwigshafen, Germany.

Dintsios CM, Krauth C, Hagen A, Gerhardus A, Schwartz FW. Innovation-related Health Technology Assessment of Cardiovascular Implants: PRE-MARKET EVALUATION OF INNOVATIVE TECHNOLOGIES CONSIDERING AS EXAMPLE VALVED VENOUS CONDUITS, HTAi 2004 (Health Technology Assessment International), Krakow May 2004, Proceedings: 57.

Hagen A, Dintsios CM, Muth C, Krauth C, Gerhardus A. Pre-market technology assessment using the Analytic Hierarchy Process (AHP) as a new method of innovation-related health technology assessment. The example of biodegradable stents. Das Gesundheitswesen 2004, 66(8/9): 571.

Dintsios CM, Hagen A, Krauth C, Gerhardus A, Schwartz FW. Pre-Market Evaluation of Innovative Technologies Considering as Example Valved Venous Condiuts. Supplementary volume of the DGBMT (German Society for Biomedical Technology), Ilmenau 2004: 656.

Hagen A, Dintsios CM, Krauth C, Gerhardus A. The Analytic Hierarchy Process (AHP) as a new way of Health Technology Assessment (iHTA)? Supplementary volume of the DGBMT (German Society for Biomedical Technology), Ilmenau 2004: 670.

Dintsios CM, Muth C, Hagen A, Krauth C, Gerhardus A, Schwartz FW. Pre-market evaluation of innovative technologies using the example of human flap-bearing venous conduits. Healthcare 2003, 8/9: A21.

Muth C, Dintsios CM, Hagen A, Krauth C, Gerhardus A, Schwartz FW. The Analytic Hierarchy Process (AHP) as a method for innovation-related health technology assessment. The Health Care System 2003, 8/9: A21.

Hagen A, Dintsios CM, Perleth M, Krauth C, Gerhardus A. Methods for the assessment of premarket biomedical innovations: A systematic review. In: The challenge of collaboration: 18th annual meeting of the International Society of Technology Assessment in Health Care-ISTAHC 2002, 87.

Dintsios CM, Hagen A, Krauth C, Gerhardus A, Schwartz FW. Innovation-related technology assessment of cardiovascular implants. In: Slesina W, Patzelt C., Weber A. (eds.): Risks and resources for health. Das Gesundheitswesen 2002, 64: A55.